The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) closed the day trading at $14.96 up 1.70% from the previous closing price of $14.71. In other words, the price has increased by $1.70 from its previous closing price. On the day, 2.73 million shares were traded. ARWR stock price reached its highest trading level at $15.03 during the session, while it also had its lowest trading level at $14.3001.
Ratios:
For a better understanding of ARWR, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.88 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 449.13. For the most recent quarter (mrq), Quick Ratio is recorded 5.15 and its Current Ratio is at 5.15. In the meantime, Its Debt-to-Equity ratio is 1.08 whereas as Long-Term Debt/Eq ratio is at 0.98.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 10 ’25 when Myszkowski Kenneth Allen bought 40,000 shares for $19.04 per share.
Anzalone Christopher Richard sold 50,800 shares of ARWR for $583,692 on Apr 11 ’25. The Chief Executive Officer now owns 3,921,255 shares after completing the transaction at $11.49 per share. On Apr 10 ’25, another insider, Anzalone Christopher Richard, who serves as the Chief Executive Officer of the company, sold 50,000 shares for $10.87 each. As a result, the insider received 543,500 and left with 3,972,055 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 2065976064 and an Enterprise Value of 1677566336. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.79 while its Price-to-Book (P/B) ratio in mrq is 3.02. Its current Enterprise Value per Revenue stands at 3.077 whereas that against EBITDA is -17.219.
Stock Price History:
The Beta on a monthly basis for ARWR is 0.95, which has changed by -0.48253202 over the last 52 weeks, in comparison to a change of 0.16260707 over the same period for the S&P500. Over the past 52 weeks, ARWR has reached a high of $29.86, while it has fallen to a 52-week low of $9.57. The 50-Day Moving Average of the stock is -7.93%, while the 200-Day Moving Average is calculated to be -15.47%.
Shares Statistics:
Over the past 3-months, ARWR traded about 1.73M shares per day on average, while over the past 10 days, ARWR traded about 2329450 shares per day. A total of 138.06M shares are outstanding, with a floating share count of 115.20M. Insiders hold about 16.58% of the company’s shares, while institutions hold 74.58% stake in the company. Shares short for ARWR as of 1751241600 were 12616251 with a Short Ratio of 7.31, compared to 1748563200 on 13310190. Therefore, it implies a Short% of Shares Outstanding of 12616251 and a Short% of Float of 11.790000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current market rating for Arrowhead Pharmaceuticals Inc (ARWR) reflects the collective analysis of 12.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.42, with high estimates of $1.05 and low estimates of -$1.48.
Analysts are recommending an EPS of between $1.57 and -$1.27 for the fiscal current year, implying an average EPS of -$0.18. EPS for the following year is -$3.45, with 13.0 analysts recommending between -$1.66 and -$4.72.
Revenue Estimates
A total of 15 analysts have provided revenue estimates for ARWR’s current fiscal year. The highest revenue estimate was $914.5M, while the lowest revenue estimate was $545.2M, resulting in an average revenue estimate of $698.31M. In the same quarter a year ago, actual revenue was $3.55MBased on 16 analysts’ estimates, the company’s revenue will be $285.94M in the next fiscal year. The high estimate is $466.95M and the low estimate is $94M.
